HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (Rapid PDF) All Versions of this Article: CJN.00500705v1 1/2/323    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Srinivas, T. R. Articles by Meier-Kriesche, H.-U. Search for Related Content PubMed PubMed Citation Articles by Srinivas, T. R. Articles by Meier-Kriesche, H.-U. Related Collections Related Articles

Received July 20, 2005
Accepted on December 13, 2005

ORIGINAL ARTICLES

Improvement in Hypercalcemia with Cinacalcet after Kidney Transplantation

Titte R. Srinivas ^*1, Jesse D. Schold ^*, Karl L. Womer , Bruce Kaplan ^*, Richard J. Howard , Charles M. Bucci ^*, and Herwig-Ulf Meier-Kriesche ^*

*Divisions of Nephrology, Hypertension and Transplantation and Nephrology and Department of Surgery, University of Florida, Gainesville, Florida; and Division of Nephrology, Gainesville Veterans Affairs Medical Center and University of Florida, Gainesville, Florida

¹ To whom correspondence should be addressed. E-mail: srinitr{at}medicine.ufl.edu.

	Abstract

Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney transplant recipients and one kidney-pancreas recipient with persistent post-Tx hypercalcemia (serum calcium [SCa] > 10.2 mg/dl), stable graft function, and intact parathyroid hormone (iPTH) 2 times normal received 30 mg/d cinacalcet between 2 mo and 5 yr after Tx. SCa, serum phosphorus (SP), and iPTH were measured before and after cinacalcet. Mean pre-cinacalcet SCa was 10.9 mg/dl (8.6 to 11.9 mg/dl). Average pre-cinacalcet SP was 2.9 mg/dl (1.8 to 4.0 mg/dl). Mean pre-cinacalcet iPTH was 267.0 pg/ml (99 to 723 pg/ml). After cinacalcet, SCa decreased on average by 1.6 mg/dl (95% confidence interval 1.2 to 2.1; P < 0.0001). Post-cinacalcet SP increased on average 0.45 mg/dl (P = 0.046). Post-cinacalcet iPTH averaged 156.9 mg/dl (P = 0.10). Graft function remained stable. Cinacalcet lowers SCa and raises SP in the short term in patients with persistent post-Tx hyperparathyroidism; long-term bone effects and persistent hyperparathyroidism merit further study.

This article has been cited by other articles:

				P. Evenepoel, B. Van Den Bergh, M. Naesens, H. De Jonge, B. Bammens, K. Claes, D. Kuypers, and Y. Vanrenterghem Calcium Metabolism in the Early Posttransplantation Period Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 665 - 672. [Abstract] [Full Text] [PDF]

				N. Kamar, I. Gennero, L. Spataru, L. Esposito, J. Guitard, L. Lavayssiere, O. Cointault, P. Gandia, D. Durand, and L. Rostaing Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3720 - 3726. [Abstract] [Full Text] [PDF]

				S. Goto, H. Komaba, and M. Fukagawa Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention NDT Plus, August 1, 2008; 1(suppl_3): iii2 - iii8. [Abstract] [Full Text] [PDF]

				M. Tanaka, S. Nakanishi, H. Komaba, K. Itoh, K. Matsushita, and M. Fukagawa Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism NDT Plus, August 1, 2008; 1(suppl_3): iii49 - iii53. [Abstract] [Full Text] [PDF]

				T. B. Drueke, D. Martin, and M. Rodriguez Reply Nephrol. Dial. Transplant., January 1, 2008; 23(1): 408 - 409. [Full Text] [PDF]

				M. Fukagawa and M. Taniguchi Can calcimimetics inhibit nodular hyperplasia of parathyroid glands? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 407 - 408. [Full Text] [PDF]

				M. Chonchol and R. P. Wuthrich Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease NDT Plus, January 1, 2008; 1(suppl_1): i36 - i41. [Abstract] [Full Text] [PDF]